Displaying drugs 14826 - 14850 of 15359 in total
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. ... Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and …
3-hydroxyisoxazole-4-carboxylic acid
Experimental
4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
Experimental
Cambendazole
Experimental
Vet approved
ISIS 14803
ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
Investigational
Matched Description: … hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and …
FT-1101
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
Matched Description: … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. …
MF268
Experimental
6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
Experimental
Benzylfentanyl
Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit
AZD-8186
AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).
Investigational
Matched Description: … AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel …
BMS-986104
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and …
3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
Experimental
(R)-Praziquantel
(R)-Praziquantel is under investigation in clinical trial NCT02271984 (Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers).
Investigational
Lorcainide
Experimental
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Matched Description: … shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and …
ONT-093
ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
Investigational
Matched Description: … In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations …
3-Mercuri-4-Aminobenzenesulfonamide
Experimental
Displaying drugs 14826 - 14850 of 15359 in total